Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 2/2013

01-04-2013 | Original Article

Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients

Authors: Jungmin Son, Soo Bong Lee, Dong Won Lee, Il Young Kim, Su Jin Lee, Sun Min Lee, Sang Heon Song, Eun Young Seong, Ihm Soo Kwak

Published in: Clinical and Experimental Nephrology | Issue 2/2013

Login to get access

Abstract

Background

In response to the pandemic 2009 A/H1N1 virus, monovalent MF59-adjuvanted vaccines were prepared. Recently, single 3.75-μg doses of MF59-adjuvanted vaccines have shown good immunogenicity in young adults. However, the immunogenicity of these vaccines has not been evaluated in dialysis patients.

Methods

Dialysis patients received a single 3.75-μg dose of MF59-adjuvanted vaccine by intramuscular injection. For immunogenicity assays, serum samples were obtained before vaccination and 28 days after vaccination. All sera were tested by hemagglutination inhibition assays.

Results

Overall, 48 hemodialysis (HD) patients and 34 peritoneal dialysis (PD) patients were included in immunogenicity analysis. In HD patients, geometric mean titers (GMTs) were significantly increased compared with baseline GMTs in both young (aged 18–60 years) and elderly (aged ≥60 years) patients (51.2 ± 51.4 vs. 14.1 ± 20.7 in young patients, P = 0.012; 37.9 ± 73.9 vs. 6.8 ± 8.0 in elderly patients, P = 0.018, respectively). The rates of seroprotection and seroconversion were 27.6 and 17.2 % in young patients and 31.6 and 26.3 % in elderly patients, respectively. Among PD patients, GMTs were increased only in young patients (39.8 ± 51.4 vs. 6.8 ± 5.0, P = 0.001). The rates of seroprotection and seroconversion were 36.0 and 36.0 % in young patients and 11.1 and 0.0 % in elderly patients, respectively.

Conclusion

A single 3.75-μg dose of MF59-adjuvanted vaccine was suboptimal to elicit protective antibody response in dialysis patients. Antibody responses against vaccine were compromised especially in elderly PD patients. Trials of different vaccination protocols such as a two-dose schedule or a higher hemagglutinin antigen dose of MF59-adjuvanted vaccine are necessary for improving antibody response in dialysis patients.
Literature
1.
2.
Nicoll A, Ammon A, Amato Gauci A, Ciancio B, Zucs P, Devaux I, et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health. 2010;124:14–23.
3.
Marcelli D, Marelli C, Richards N. Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant. 2009;24:3566–72.PubMedCrossRef
4.
Johansen K, Nicoll A, Ciancio BC, Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill. 2009;14:19361.PubMed
5.
Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med. 2006;354:1343–51.PubMedCrossRef
6.
Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13.PubMedCrossRef
7.
Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009;361:2424–35.PubMedCrossRef
8.
Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361:2414–23.PubMedCrossRef
9.
Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: preliminary report of an observer-blind, randomized trial. Vaccine. 2010;28:1740–5.PubMedCrossRef
10.
11.
Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA. 2008;105:10501–6.PubMedCrossRef
12.
Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine. 2009;27:3331–4.PubMedCrossRef
13.
Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol. 2011;18:1358–64.PubMedCrossRef
14.
Leypoldt JK. Urea standard Kt/V for assessing dialysis treatment adequacy. Hemodial Int. 2004;8:193–7.PubMedCrossRef
15.
Nolph KD, Moore HL, Twardowski ZJ, Khanna R, Prowant B, Meyer M, et al. Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J. 1992;38:M139–42.PubMedCrossRef
16.
17.
18.
Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens. 1993;2:883–91.PubMedCrossRef
19.
Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int Suppl. 1993;41:S135–42.PubMed
20.
Haag-Weber M, Horl WH. Uremia and infection: mechanisms of impaired cellular host defense. Nephron. 1993;63:125–31.PubMedCrossRef
21.
Hanquet G, Van Damme P, Brasseur D, De Cuyper X, Gregor S, Holmberg M, et al. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine. 2011;29:370–7.PubMedCrossRef
22.
de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73.
23.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767–77.CrossRef
24.
Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006;103:c89–93.PubMedCrossRef
25.
Ramezani A, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract. 2009;63:394–7.PubMedCrossRef
26.
Edey M, Barraclough K, Johnson DW. Review article: hepatitis B and dialysis. Nephrology (Carlton). 2010;152:137–45.CrossRef
27.
Song JY, Cheong HJ, Ha SH, Kee SY, Jeong HW, Kim WJ. Active influenza immunization in hemodialysis patients: comparison between single-dose and booster vaccination. Am J Nephrol. 2006;26:206–11.PubMedCrossRef
28.
Scharpé J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis. 2009;54:77–85.PubMedCrossRef
29.
Antonen JA, Hannula PM, Pyhala R, Saha HH, Ala-Houhala IO. Pasternack AI. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000;86:56-61.
30.
Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003;37:71–6.PubMedCrossRef
31.
Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al., Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep. 2007;56:1–54.
32.
Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial. 2000;13:101–7.PubMedCrossRef
33.
Mulley WR, Visvanathan K, Hurt AC, Brown FG, Polkinghorne KR, Mastorakos T, et al. Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney Int. 2012. doi:10.​1038/​ki.​2012.​106 (Epub ahead of print).
34.
Labriola L, Hombrouck A, Maréchal C, Van Gucht S, Brochier B, Thomas I, et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant. 2011;26:1424–8.PubMedCrossRef
35.
Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis. 2011;57:716–23.PubMedCrossRef
36.
Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, Aranio D, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol. 2011;49:2210–5.PubMedCrossRef
37.
Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41–8.PubMedCrossRef
38.
Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2010;375:56–66.PubMedCrossRef
39.
Crespo M, Collado S, Mir M, Cao H, Barbosa F, Serra C, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol. 2011;6:2208–14.PubMedCrossRef
40.
Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine. 2011;29:523–7.PubMedCrossRef
41.
Temiz G, Kasifoglu N, Kiris A, Ozturk S, Sahin G, Yalcin AU, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail. 2010;32:716–20.PubMedCrossRef
42.
Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging. 2011;28:93–106.PubMedCrossRef
43.
Giacchino F, Quarello F, Pellerey M, Piccoli G. Continuous ambulatory peritoneal dialysis improves immunodeficiency in uremic patients. Nephron. 1983;35:209–10.PubMedCrossRef
44.
Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardoski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. Ann Intern Med. 1978;88:448–52.CrossRef
45.
Touraine JL, Touraine F, Revillard JP, Brochier J, Traeger J. T lymphocytes and serum inhibitors of cell-mediated immunity in renal insufficiency. Nephron. 1975;14:195–208.PubMedCrossRef
46.
Versluis DJ, Beyer WE, Masurel N, Diderich PP, Kramer P, Weimar W. Intact humoral immune response in patients on continuous ambulatory peritoneal dialysis. Nephron. 1988;49:16–9.PubMedCrossRef
47.
Antonen JA, Hannula PM, Pyhälä R, Saha HH, Ala-Houhala IO, Pasternack AI. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000;86:56–61.PubMedCrossRef
48.
Fabrizi F, Dixit V, Bunnapradist S, Martin P. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006;23:1105–12.PubMedCrossRef
49.
Lin SY, Liu JH, Lin CC, Wang SM, Tsai CA, Chou CY, et al. Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients. Vaccine. 2011;29:3738–41.PubMedCrossRef
50.
Deans GD, Stiver HG, McElhaney JE. Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med. 2010;267:220–7.PubMedCrossRef
51.
Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, et al. The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with type 2 diabetes mellitus in Korea. Diabet Med. 2011;28:815–7.PubMedCrossRef
52.
Fabrizi F, Dixit V, Martin P, Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther. 2011;33:815–21.PubMedCrossRef
Metadata
Title
Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients
Authors
Jungmin Son
Soo Bong Lee
Dong Won Lee
Il Young Kim
Su Jin Lee
Sun Min Lee
Sang Heon Song
Eun Young Seong
Ihm Soo Kwak
Publication date
01-04-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0696-1

Other articles of this Issue 2/2013

Clinical and Experimental Nephrology 2/2013 Go to the issue

Original Article

Comparison of effective impact among tonsillectomy alone, tonsillectomy combined with oral steroid and with steroid pulse therapy on long-term outcome of immunoglobulin A nephropathy

Original Article

Stiffness parameter β as a predictor of the 4-year all-cause mortality of chronic hemodialysis patients

Special Report

Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010

Original Article

The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects

Original Article

Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease

Original Article

Glomerular expression of connexin 40 and connexin 43 in rat experimental glomerulonephritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits